看到您的产品的真正潜力。
iqviaPipeline Architect brings the commercial future into sharper focus during clinical trials, so you can streamline your development process and prioritize the most promising compounds.
Use data to drive development decisions
一种识别化合物未来价值的客观，分析方法可以简化您的投资组合，并在策略上更加重点。
IQVIA的管道架构师是一个技术平台，可从32,000多个临床试验中获取数据，并使用来自4,000多种产品的数据预测商业资产价值。
This data is then combined with information from across your organization - from regulatory and clinical to commercial and portfolio groups - to enable truly precise scenario planning.
Pipeline Architect delivers integrated workflows, access to clinical and commercial data, and a platform to create, benchmark, and refine plans. All without adding extra resources.
一个平台推动结果
Pipeline Architect将最佳实践带入了范围，所有这些都是基于世界上最大的综合临床和商业数据库之一。
- Identifying ways to save on clinical trial costs and shave time off development plans
- 使用包含行业数据的预先配置的设计库快速有效地生成新的开发计划
- 访问一流的决策科学方法，并以精致的定量措施支持，以管理风险并优化您的资产的全部价值
利用伊克维亚核心的力量手机版必威
IQVIA将深入的治疗和科学知识与世界上最大的策划医疗保健数据的来源之一相结合。必威手机APP我们将现实世界中匿名患者数据的各种流与全球商业数据集成在一起。为什么？因为我们想帮助您更快地达到里程碑，并从一开始就可以与您的疗法区分开。
Access new resources for advanced therapy development, from candidate identification through market authorization.
Capture the patient experience across the full trial process, from strategy to dissemination of results.
Use machine learning-driven analytics to help identify promising patient subgroups, potentially preserving your investment and ensuring valuable therapies reach patients.
Leverage a global network of Phase I clinical pharmacology units to build diversity in patient populations and access a range of geographic regions for early clinical development (ECD) programs.
通过IQVIA核心的力量提高临床试验的性能。手机版必威
使用先进的分析来评估您针对现实世界证据的协议，并降低昂贵修订的风险。
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
使用数据驱动的患者招聘解决方案来更准确地预测入学率，并增加每个部位的患者数量。
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.